Summit Therapeutics Inc.'s SEC filings document the company's oncology development business, regulatory updates, governance, and capital structure. Form 8-K reports cover financial results, Regulation FD presentations, ivonescimab clinical data, FDA acceptance of the Biologics License Application, and clinical collaboration disclosures involving investigational cancer combinations.
Definitive proxy materials describe board matters, executive compensation, equity awards, shareholder voting items, and governance practices. The filing record also includes material-event disclosures, material agreements, operating and financial results, and capital-structure information for Summit's Nasdaq-listed common stock and its development rights to ivonescimab.
Summit Therapeutics Inc. reported that director Kenneth A. Clark received new stock option awards. On January 2, 2026, he was granted 35,000 stock options with an exercise price of $17.52 per share, vesting in four quarterly installments during the year of grant, as long as he continues serving as a non-salaried director on each vesting date. On the same date, he also received a separate grant of 17,796 stock options with the same exercise price, issued under the company’s Director Retainer Option Election Plan in lieu of $155,900 of cash retainer fees. All reported options are held directly.
Summit Therapeutics Inc. reported that director Alessandra Cesano received new stock option awards. On 01/02/2026, she was granted a stock option for 35,000 shares of common stock at an exercise price of $17.52 per share, expiring on 01/02/2036. These shares vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the grant year, as long as she continues serving as a non-salaried director.
She was also granted a separate stock option for 3,219 shares of common stock at the same $17.52 exercise price, expiring on 01/02/2036. This option was issued under the company’s Director Retainer Option Election Plan in lieu of cash retainer fees of $28,200 and vests in four quarterly installments on March 31, June 30, September 30 and December 31 following her election, contingent on continued board service.
Summit Therapeutics (SMMT) reported that its partner Akeso published final overall survival results from the Phase III HARMONi-A trial in China. The study tested ivonescimab plus platinum-doublet chemotherapy versus chemotherapy alone in EGFR‑mutated, locally advanced or metastatic non-squamous NSCLC after EGFR TKI therapy.
Ivonescimab plus chemotherapy achieved a statistically significant and clinically meaningful overall survival benefit with a hazard ratio of 0.74 (95% CI: 0.58, 0.95; p=0.019). Median OS was 16.8 months (95% CI: 14.5, 20.0) versus 14.1 months (95% CI: 12.8, 16.3) for chemotherapy alone. The analysis used an April 2025 data cut-off and had a 32.5‑month median follow-up. Summit furnished these data via a press release attached as Exhibit 99.1.
Summit Therapeutics (SMMT) reported an insider transaction by director Yu Xia. On 10/21/2025, she acquired 533,617 shares of common stock at $18.74 per share in a private placement pursuant to a definitive agreement, anticipated to close on or about 10/23/2025. After the transaction, 32,057,147 shares were beneficially owned indirectly through Akeso, Inc. Dr. Xia disclaims beneficial ownership of Akeso’s holdings except to the extent of her pecuniary interest.
Summit Therapeutics (SMMT) insider transaction: Chief Accounting Officer Bhaskar Anand reported acquiring 26,680 shares of common stock at $18.74 per share on 10/21/2025. The shares were acquired in a private placement under a definitive agreement dated October 21, 2025, with the transaction anticipated to close on or about October 23, 2025.
Following the reported transaction, Anand beneficially owned 159,751 shares directly. Holdings include shares previously acquired through the company’s employee stock purchase plan.
Summit Therapeutics Inc. (SMMT) reported an insider purchase by its COO and CFO, who is also a director. On 10/21/2025, the reporting person acquired 53,361 shares of common stock at $18.74 per share, coded as an acquisition (A).
Following this transaction, the reporting person beneficially owned 3,073,603 shares, held directly. The shares were acquired in a private placement under a definitive agreement dated October 21, 2025, with the transaction anticipated to close on or about October 23, 2025.
Summit Therapeutics (SMMT) Co‑CEO, director, and 10% owner Robert W. Duggan reported acquisitions of common stock. He acquired 13,980,789 shares at $18.74 in a private placement pursuant to a definitive agreement dated October 21, 2025, anticipated to close on or about October 23, 2025. He also acquired 266,808 shares indirectly at $18.74 and purchased 26,680 shares at $18.74.
Following these transactions, he beneficially owned 570,073,879 shares directly and 25,724,474 shares indirectly via a trust, with additional indirect holdings of 76,680, 31,000, and 10,199,776 shares through family and related trusts.
Summit Therapeutics (SMMT) Co‑Chief Executive Officer and director Mahkam Zanganeh, a 10% owner, reported multiple share purchases dated 10/21/2025 tied to a private placement at $18.74 per share. Reported acquisitions include 266,808 shares by the Mahkam Zanganeh Revocable Trust, 26,680 shares for an immediate family member, and 13,980,789 shares by her spouse. The filing notes the transaction was pursuant to a definitive agreement and is anticipated to close on or about October 23, 2025. The report includes a standard disclaimer of beneficial ownership for certain indirect holdings.
Summit Therapeutics Inc. announced a private placement of 26,682,846 shares of common stock at $18.74 per share, matching the October 21, 2025 closing price, for aggregate gross proceeds of approximately $500.0 million. The financing is a primary issuance and is expected to close on or before October 28, 2025, subject to customary closing conditions.
Company leaders and employees participated, purchasing an aggregate of 14,514,402 shares, and Akeso, Inc. purchased 533,617 shares. The shares are being issued in reliance on Section 4(a)(2) and Regulation D exemptions. Summit agreed to file a registration statement to register the resale of these shares as soon as reasonably practicable and no later than December 19, 2025, and to use reasonable best efforts to have it declared effective.
Summit Therapeutics Inc. filed a Form 4 disclosing an equity award to Anand Bhaskar, the company's Chief Accounting Officer. On 09/18/2025 Mr. Bhaskar was granted a stock option to purchase 50,000 shares of common stock at an exercise price of $19.23 per share.
The option vests in four equal annual installments with the first vesting on 09/18/2026 and expires on 09/18/2035. After the grant, Mr. Bhaskar beneficially owns 50,000 underlying shares directly. The Form 4 was signed on 09/19/2025.